The timeframe when the deal took place was about the same time Peddar came on board. The general belief is that Delcath BOD and Simpson received some type of offer pending cleaning up the books and regaining control of their 20+ Patents. Once the SP dropped below the requirement last year to stay listed on NASDAQ, the BOD recommended a R/S. Well, the shareholders said no, and then the company had to be delisted for compliance and found itself on the OTC. With all that was happening, they needed money in order to keep the trials going, so they found no choice but to hop into bed with HB...whom wanted the Company to fail because HB wanted all of Delcath's patents. It appears now that DCTH was able to find a way to give back the money after doing the horrible R/S last year, and then issuing another 123M shares and cash to HB. HB made out well by getting to sell their shares at a huge conversion price! Every sell they made down to about 2.5 cents was still profit! They had no incentive to let the SP organically rise...they were making money hand over foot no matter the share price!
Then the selling stops...which is where we are now. DCTH has control of their patents, DCTH has no outstanding debt, DCTH has agreed Protocol Assessment with the FDA for relaxed enrollment criteria for their FOCUS Trial, DCTH is working with FDA for early approval, DCTH has received their blessing from the Independent Safety Monitoring Committee on the FOCUS Trial, DCTH intends to start the Phase 3 ICC Trial in March, DCTH has completed more than 500 procedures in Europe, DCTH is approved by the EU for treatments in Europe!
NEXT UP FDA APPROVAL!
IMHO
In My Own Personal Opinion Of Course!
